Interventions
neutropenia, diarrhea, thrombocytopenia, anemia, constipation, nausea,
ADVERSE EVENT, NEUTROPENIA, THROMBOCYTOPENIA, ANEMIA, ADVERSE REACTION, EVENTS
Figure Design of the MEDAL trialIf an adverse reaction occurs due to radium-223 administration, the degree of the adverse reaction should be evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, and the dose should be withdrawn or reduced. In case of grade 3 or higher neutropenia, anemia, or thrombocytopenia, administration should be postponed until recovery to grade 2 or lower, and then resumed after confirmation of recovery. If the grade of neutropenia or thrombocytopenia does not recover to grade 2 or below within 6 weeks of the last dose, administration should be discontinued. For grade 3 or higher diarrhea, nausea, vomiting, or constipation, postpone administration until recovery to grade 2 or lower, and resume administration after confirming recovery. If grade 4 events persist for more than 7 days, administration should be discontinued.